Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial

A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease

(2010) I. Dotan et al.   GUT

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up

(2009) Shane M. Devlin et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Safety Profile of IBD: Lymphoma Risks

(2009) Meenakshi Bewtra et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease

(2008) Jennifer Jones et al.   Clinical Gastroenterology and Hepatology

Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease

(2008) Murat Toruner et al.   GASTROENTEROLOGY

Hepatosplenic T cell lymphoma in inflammatory bowel disease

(2008) M. Shale et al.   GUT

The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease

(2008) Gail L. Matters et al.   Journal of Immunotoxicology